Article Text
Therapeutics
Randomised controlled trial
In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting β agonists provided equivalent short-term asthma quality of life but were associated with more medication switches
Statistics from Altmetric.com
Footnotes
-
Competing interests Yes – JMFG has received fees from AstraZeneca, GSK, Merck, BI and Novartis and Nycomed for lectures, advisory committees, travel grants or consultancy services. He has also received fees or grants paid and used for research, education, equipment or salaries from GSK, BI, Wyeth, Genentech, Topigen, Canadian Institute for Health Research, Medimmune, Pharmaxis, Novartis and AllerGen NCE. Finally, he does not have shares in the asthma-related pharmaceutical/medical device industry, excluding pension plans, mutual funds or unit trusts..